No Data
No Data
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
NANJING, China, March 26, 2024 /PRNewswire/ -- PharmaBlock (Stock code: 300725.SZSE), a global, fully integrated CRDMO with a focus on innovative chemistry and low-carbon manufacturing, is proud to an
Yakshi Technology won the 2024 ACS CMO Green Chemistry Excellence Award
Nanjing, March 26, 2024 /PRNewswire/ -- Nanjing Pharmaceutical Technology Co., Ltd. (Company abbreviation: “Pharmaceutical Stone Technology”, stock code: 300725.SZSE), as a global integrated CRDMO company focusing on innovative chemistry and low-carbon manufacturing, recently won the American Chemical Society (ACS) Green Chemistry Institute Pharmaceutical Roundtable (Green Chemistry Institute Pharmaceutical) Roundtable,
Optimistic Investors Push PharmaBlock Sciences (Nanjing), Inc. (SZSE:300725) Shares Up 30% But Growth Is Lacking
Those holding PharmaBlock Sciences (Nanjing), Inc. (SZSE:300725) shares would be relieved that the share price has rebounded 30% in the last thirty days, but it needs to keep going to repair the recen
These 4 Measures Indicate That PharmaBlock Sciences (Nanjing) (SZSE:300725) Is Using Debt Extensively
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
PharmaBlock Sciences (Nanjing), Inc.'s (SZSE:300725) Earnings Haven't Escaped The Attention Of Investors
With a median price-to-earnings (or "P/E") ratio of close to 30x in China, you could be forgiven for feeling indifferent about PharmaBlock Sciences (Nanjing), Inc.'s (SZSE:300725) P/E ratio of 29.2x.
[BT Financial Report Momentary Analysis] Yakshi Technology's 2023 Quarterly Report: Financial Perspectives Behind Steady Growth in Performance
Pharmaceutical Stone Technology (stock code: 300725), as a global leader in pharmaceutical R&D and manufacturing, provides one-stop services from molecular block development to drug discovery solutions. The company focuses on chemical and low-carbon technology innovation, and is committed to improving the efficiency of new drug discovery and development while reducing drug production costs. Yakshi Technology's molecular block library is rich in variety, novel in structure and efficient, and has successfully covered many key stages of new drug development. In terms of assets and liabilities, Yakshi Technology's 2023 three-quarter report shows that the company's total assets reached 5.217 billion yuan, up from 4.862 billion yuan at the end of the previous year
No Data